Episode 23: ASCO Annual Meeting 2025 Commentary: Kidney Cancer

https://is1-ssl.mzstatic.com/image/thumb/Podcasts116/v4/d2/9a/09/d29a09bb-6bb4-d3b6-1911-aad1979f4b90/mza_8029225495197491321.jpg/600x600bb.jpg

The View on GU | with Lalani and Wallis

Dr. Aly-Khan Lalani & Dr. Christopher Wallis

33 episodes

2 days ago

There is currently a lack of organic multi-disciplinary discussion on what is truly impactful to the field of genitourinary (GU) cancers. The View on GU with Lalani and Wallis is a podcast that will integrate key clinical data from major conferences and high impact publications into meaningful take home messages for practicing clinicians. Importantly, Lalani and Wallis will also discuss the impact of governmental approvals and funding considerations on the GU oncology treatment landscape and provide practical considerations on the management of patients on new-to-market therapies.

Medicine

Health & Fitness

RSS

All content for The View on GU | with Lalani and Wallis is the property of Dr. Aly-Khan Lalani & Dr. Christopher Wallis and is served directly from their servers with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.

Medicine

Health & Fitness

https://d3t3ozftmdmh3i.cloudfront.net/staging/podcast_uploaded_nologo/40427888/41d07e9c28fc00dc.jpeg

Episode 23: ASCO Annual Meeting 2025 Commentary: Kidney Cancer

The View on GU | with Lalani and Wallis

29 minutes 23 seconds

5 months ago

Episode 23: ASCO Annual Meeting 2025 Commentary: Kidney Cancer

Recorded live in Chicago, your hosts explore the latest in kidney cancer, discussing new five-year follow-up data from KEYNOTE-564, the long-term results of CheckMate 214, insights from the ongoing PDIGREE trial, and much more.

The View on GU with Lalani & Wallis integrates key clinical data from major conferences and high impact publications, sharing meaningful take home messages for practising clinicians in the field of genitourinary (GU) cancers. Learn more about The View on GU: theviewongu.ca

This podcast has been made possible through unrestricted financial support by Novartis, Bayer, Astellas, Tolmar, Ipsen, J&J, Merck, Pfizer, Eisai and AbbVie.